Home » Drug Information » FDA Approved Drugs » 1995
Medical Areas: Immunology | Otolaryngology (Ear, Nose, Throat) | Pulmonary/Respiratory Diseases | Family Medicine | Infections and Infectious Diseases
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Approval Status: Approved December 1995
Treatment Area: chronic bronchitis, infection of the middle ear, pharyngitis/tonsillitis
Clinical studies have demonstrated that Cedax is active against
a broad spectrum of bacteria that are common causes of upper and
lower respiratory tract infections. These include most strains of
Haemophilus influenzae, Moraxella catarrhalis, Streptococcus
pneumoniae, and Streptococcus pyogenes. Cedax is highly stable in
the presence of beta-lactamases--enzymes produced by bacteria that
can render some commonly used antibiotics, such as amoxicillin or
Clinical trials revealed a very low incidence of
gastrointestinal side effects, including diarrhea.
Acute otitis media is the most commonly diagnosed infection
among children today. By age three, 84 percent of all children will
have experienced at least one episode of acute otitis media, and
nearly 50 percent will have had three or more episodes.
Acute bacterial exacerbation of chronic bronchitis is a
bacterial infection that frequently occurs in chronic bronchitis
subjects. According to the American Lung Association, chronic
bronchitis affects at least 13.8 million Americans.